|
Synonyms: MGN-1703 | MGN1703
Compound class:
Nucleic acid
Comment: Lefitolimod (MGN-1703) is a CpG oligonucleotide that was intended to act as a Toll-like receptor 9 (TLR9) agonist to stimulate innate and adaptive immunity. It behaves as a double-stem loop immunomodulator, with CpG motifs at both ends.
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
| References |
|
1. Gunst JD, Højen JF, Pahus MH, Rosás-Umbert M, Stiksrud B, McMahon JH, Denton PW, Nielsen H, Johansen IS, Benfield T et al.. (2023)
Impact of a TLR9 agonist and broadly neutralizing antibodies on HIV-1 persistence: the randomized phase 2a TITAN trial. Nat Med, 29 (10): 2547-2558. [PMID:37696935] |
|
2. Kapp K, Volz B, Oswald D, Wittig B, Baumann M, Schmidt M. (2019)
Beneficial modulation of the tumor microenvironment and generation of anti-tumor responses by TLR9 agonist lefitolimod alone and in combination with checkpoint inhibitors. Oncoimmunology, 8 (12): e1659096. [PMID:31741757] |
|
3. Krarup AR, Abdel-Mohsen M, Schleimann MH, Vibholm L, Engen PA, Dige A, Wittig B, Schmidt M, Green SJ, Naqib A et al.. (2018)
The TLR9 agonist MGN1703 triggers a potent type I interferon response in the sigmoid colon. Mucosal Immunol, 11 (2): 449-461. [PMID:28766555] |
|
4. Nardo M, Gouda MA, Reilley MJ, Biter AB, Lim J, Bean SA, Nguyen LM, Bhosale PR, Ager CR, Couillault CA et al.. (2025)
Lefitolimod in Combination with Ipilimumab in Patients with Advanced Solid Tumors: A Phase I Trial. J Immunother Precis Oncol, 8 (2): 89-98. [PMID:39959251] |
|
5. Reilley MJ, Morrow B, Ager CR, Liu A, Hong DS, Curran MA. (2019)
TLR9 activation cooperates with T cell checkpoint blockade to regress poorly immunogenic melanoma. J Immunother Cancer, 7 (1): 323. [PMID:31771649] |
|
6. Thomas M, Ponce-Aix S, Navarro A, Riera-Knorrenschild J, Schmidt M, Wiegert E, Kapp K, Wittig B, Mauri C, Dómine Gómez M et al.. (2018)
Immunotherapeutic maintenance treatment with toll-like receptor 9 agonist lefitolimod in patients with extensive-stage small-cell lung cancer: results from the exploratory, controlled, randomized, international phase II IMPULSE study. Ann Oncol, 29 (10): 2076-2084. [PMID:30137193] |
|
7. Vibholm LK, Konrad CV, Schleimann MH, Frattari G, Winckelmann A, Klastrup V, Jensen NM, Jensen SS, Schmidt M, Wittig B et al.. (2019)
Effects of 24-week Toll-like receptor 9 agonist treatment in HIV type 1+ individuals. AIDS, 33 (8): 1315-1325. [PMID:30932955] |
|
8. Wittig B, Schmidt M, Scheithauer W, Schmoll HJ. (2015)
MGN1703, an immunomodulator and toll-like receptor 9 (TLR-9) agonist: from bench to bedside. Crit Rev Oncol Hematol, 94 (1): 31-44. [PMID:25577571] |